Journal: International Journal of Molecular Sciences

Article Title: TRPA1-Related Diseases and Applications of Nanotherapy

doi: 10.3390/ijms25179234

Figure Lengend Snippet: Application of nanotechnology in breast cancer and PMA treatment targeting TRPA1 inhibition. ( a ) Nanoparticle-encapsulated antagonist DIPMA-MK-3207, a pH-responsive nanoparticle targeting endosomal CLR/RAMP1, enhances CGRP-induced pain relief efficacy by blocking TRPA1-related signaling.; ( b ) photothermal conjugated polymer nanoparticles (NPs-H) encapsulating HC-030031 (HC), a specific inhibitor of the near-infrared (NIR)-responsive TRPA1 ion channel, block the formation of Ca 2+ /CaM complexes when exposed to an 808 nm laser. As a result, chemotherapy resistance is reduced and tumor cell death is promoted. Red arrows: Pathway of disease suppression by nanoparticles, blue arrows: Pathway of disease development by TRPA1 activation.

Article Snippet: In a recent study, biomimetic conjugated oligomeric nanoparticles (CM-CON) with NIR-II imaging capabilities, ROS generation, and photothermal effects were developed using an “acceptor-donor” conjugated oligomer (S81CF) encapsulated in endocrine cell membranes [ ].

Techniques: Inhibition, Blocking Assay, Polymer, Activation Assay

Journal: International Journal of Molecular Sciences

Article Title: TRPA1-Related Diseases and Applications of Nanotherapy

doi: 10.3390/ijms25179234

Figure Lengend Snippet: Application of nanotechnology in MS and KOA treatment targeting TRPA1 inhibition. ( a ) The use of solid lipid nanoparticles (SLNs) to deliver anti-inflammatory drugs with poor bioavailability could improve drug stability and delivery, potentially enabling effective MS treatment to prevent demyelination by inhibiting the TRPA1/NF-kB/GFAP signaling pathway.; ( b ) Nanoemulsion (SP-NE) with excellent stability, manufactured by extracting essential oil from pickling powder, a herbal medicine for KOA, through a high-pressure homogenization process, alleviates KOA synovitis by negatively regulating TRPA1 through AMPK-mTOR signaling. Red arrows: Pathway of disease suppression by nanoparticles, blue arrows: Pathway of disease development by TRPA1 activation.

Article Snippet: In a recent study, biomimetic conjugated oligomeric nanoparticles (CM-CON) with NIR-II imaging capabilities, ROS generation, and photothermal effects were developed using an “acceptor-donor” conjugated oligomer (S81CF) encapsulated in endocrine cell membranes [ ].

Techniques: Inhibition, Homogenization, Activation Assay

Journal: International Journal of Molecular Sciences

Article Title: TRPA1-Related Diseases and Applications of Nanotherapy

doi: 10.3390/ijms25179234

Figure Lengend Snippet: Application of nanotechnology on tumor and diabetes treatment targeting TRPA1 activation. Tumor: NIR light-irradiated silica nanoparticles (MSNs) with tumor cell targeting properties, I/B@MSN-T@HA (light-controlled Ca 2+ na-modulator), trigger ROS generation and Ca 2+ influx through TRPA1 channels. This approach maximizes intracellular Ca 2+ concentration, resulting in mitochondrial dysfunction, ATP reduction, and tumor cell death (red arrows); ROS generation, and photothermal effects are exposed to an 808 nm laser, they generate ROS and local heat to activate the TRPA1 ion channel. Ca 2+ introduced into cells by activation increases GLP-1 secretion and lowers blood sugar levels (blue arrows).

Article Snippet: In a recent study, biomimetic conjugated oligomeric nanoparticles (CM-CON) with NIR-II imaging capabilities, ROS generation, and photothermal effects were developed using an “acceptor-donor” conjugated oligomer (S81CF) encapsulated in endocrine cell membranes [ ].

Techniques: Activation Assay, Irradiation, Concentration Assay